A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624

DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities. The objectives of the planned clinical investigation will be to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and multiple-ascending doses of DR10624 via subcutaneous (SubQ) injection in a randomized, placebo-controlled, double-blind study.

Inclusion Criteria: 1. The subject is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead ECG results, and physical examination findings at screening. 2. Female subjects (heterosexually active, of childbearing potential, not pregnant, not trying to become pregnant, and not lactating) are eligible to participate if they agree to total abstinence from heterosexual intercourse or use a highly effective method of birth control listed below, from screening through until at least 30 days after the last dose of the study drug. Male subjects with female partners of childbearing potential are eligible to participate if they are vasectomized, or agree to total abstinence from heterosexual intercourse, from screening through until at least 30 days after the last study dose, or use of an effective method of birth control listed above, from screening through until at least 30 days after the last study dose. Male subjects must refrain from sperm donation throughout the study and for 30 days after the last study dose. 3. The subject agrees to comply with all protocol requirements. 4. The subject is able to provide written informed consent. Additional inclusion criteria for Part 1: 1. The subject is male or female 18 to 55 years of age, inclusive. 2. The subject has a body weight ≥50 kg at screening and a BMI of 18 to 32 kg/m2, inclusive, or. 3. The subject has a BMI of 30 to 40 kg/m2, inclusive, at screening in obesity subjects cohort. Additional inclusion criteria for Part 2: 1. The subject is male or female 18 to 60 years of age, inclusive. 2. The subject has a BMI of 30 to 45 kg/m2 at screening, inclusive. 3. Fasting triglyceride ≥150 mg/dL (1.7 mmol/L), and \10.3 mmol/L or triglycerides ≥5.7 mmol/L (500 mg/dL) at screening. 12. The subject has clinically significant history or presence of ECG findings as determined by the investigator at screening and check-in, \- Uncontrolled hypertension (defined as systolic blood pressure (SBP) ≥160 mmHg, and/or diastolic blood pressure (DBP) ≥100 mmHg), angina, bradycardia (if assessed as clinically significant by the investigator), or severe peripheral arterial circulatory disorders. 13. The subject has a history of relevant drug and/or food allergies (ie, allergy to DR10624 or excipients, or any significant food allergy that could preclude a standard diet in the clinical unit). 14. The subject has a history of severe allergic or anaphylactic reactions. 15. The subject has experienced a \>5% loss in body weight within 2 months prior to screening. 16. Female subjects who are pregnant or lactating. 17. The subject has a positive test for severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). A positive rapid antigen test (RAT), isothermal nucleic acid amplification, or polymerase chain reaction (PCR) coronavirus disease-2019 (COVID-19) test during screening or at admission is acceptable provided the subject has a known previous COVID-19 infection ≥3 weeks prior to dosing, has recovered, and is now asymptomatic 18. The subject has received study drug in another investigational study within 30 days of dosing. 19. In the opinion of the investigator, the subject is not suitable for entry into the study. Additional exclusion criteria for subjects in Part 2: 1. Subjects with coagulopathies. 2. Poorly controlled diabetes, defined as HbA1c \>8.5% at screening. 3. The subject has been treated with the following anti-diabetic agents, glucagon-like peptide-1 receptor agonist (GLP-1Ra), dipeptidyl peptidase-4 inhibitors (DPP-4i), or insulin, within 30 days prior to screening until the follow-up visit. 4. The subjects have \>2 × upper limit of normal (ULN) of either alanine aminotransferase (ALT) or aspartate aminotransferase (AST), or \>1.5 × ULN for bilirubin or alkaline phosphatase at screening. 5. Subjects with contraindications to MRI.